Arginine mediated photodynamic therapy with silicon(IV) phthalocyanine photosensitizers.

In the current study, we synthesized a new SiPc derivative conjugated with arginine at the axial positions, for a novel phthalocyanine-based photosensitizer for photodynamic therapy (PDT) applications in cancer cells. Axially-di-arginine substituted new silicon(IV) phthalocyanine photosensitizer (PS-5a) has been thoroughly researched for its anti-cancer properties. Various spectroscopic techniques were used to characterize this conjugate, including ¹ H NMR, ¹³ C NMR, FT-IR, UV-vis, and MS spectral data. The in vitro PDT activities of the conjugate on cancer cells were tested through its cytotoxic, clonogenic, apoptotic effects on, and its capacity to induce DNA damage, and the disruption of mitochondrial membrane potential in cancer cell lines (liver; HuH-7, cervix; HeLa and breast; MCF7). Cancer cells exposed to the light illumination following uptake of the PS-5a as a photosensitizer revealed DNA breakage and collapsed mitochondrial membrane potential. The results of the present investigation demonstrate that PS-5a has a significant photo-cytotoxic effect on cancer cells. So, axially-di-arginine substituted silicon(IV) phthalocyanine could be an effective PDT agent for PDT treatment.
Competing Interests: Declaration of Competing Interest There are no conflicts to declare.
(Copyright © 2023 Elsevier B.V. All rights reserved.)